167Matsuda N, Jesmin S, Takahashi Y, Hatta E, Kobayashi M, Matsuyama K et al (2004) Histamine
H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents
and humans. J Pharmacol Exp Ther 309:786–795
Mazza R, Mannarino C, Imbrogno S, Barbieri SF, Adamo C, Angelone T et al (2007) Crucial role
of cytoskeleton reorganization in the negative inotropic effect of chromogranin A-derived pep-
tides in eel and frog hearts. Regul Pept 138:145–151
Mazza R, Gattuso A, Mannarino C, Brar BK, Barbieri SF, Tota B et al (2008) Catestatin (chromo-
granin A344-364) is a novel cardiosuppressive agent: inhibition of isoproterenol and endothe-
lin signaling in the frog heart. Am J Physiol Heart Circ Physiol 295:H113–H122
Mazza R, Tota B, Gattuso A (2015) Cardio-vascular activity of catestatin: interlocking the puzzle
pieces. Curr Med Chem 22:292–304
Mellor P, Furber LA, Nyarko JN, Anderson DH (2012) Multiple roles for the p85α isoform in
the regulation and function of PI3K signalling and receptor trafficking. Biochem J 441:23–37
Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB (2003) Caveolin regulation of endo-
thelial function. Am J Physiol Lung Cell Mol Physiol 285:L1179–L1183
Nicholls DP, Onuoha GN, McDowell G, Elborn JS, Riley MS, Nugent AM et al (1996)
Neuroendocrine changes in chronic cardiac failure. Basic Res Cardiol 91(Suppl 1):13–20
Niles WD, Malik AB (1999) Endocytosis and exocytosis events regulate vesicle traffic in endothe-
lial cells. J Membr Biol 167:85–101
O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ (2002) Early
decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of
hypertension. J Hypertens 20:1335–1345
Pasqua T, Corti A, Gentile S, Pochini L, Bianco M, Metz-Boutigue MH et al (2013) Full-length
human chromogranin-A cardioactivity: myocardial, coronary, and stimulus-induced process-
ing evidence in normotensive and hypertensive male rat hearts. Endocrinology 154:3353–3365
Penna C, Alloatti G, Gallo MP, Cerra MC, Levi R, Tullio F et al (2010) Catestatin improves post-
ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell Mol
Neurobiol 30:1171–1179
Perrelli MG, Tullio F, Angotti C, Cerra MC, Angelone T, Tota B et al (2013) Catestatin reduces
myocardial ischaemia/reperfusion injury: involvement of PI3K/Akt, PKCs, mitochondrial
KATP channels and ROS signalling. Pflugers Arch 465:1031–1040
Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B et al (2007) Myocardial production
of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart
J 28:1117–1127
Poon GM, Gariepy J (2007) Cell-surface proteoglycans as molecular portals for cationic peptide
and polymer entry into cells. Biochem Soc Trans 35:788–793
Rabenstein DL (2002) Heparin and heparan sulfate: structure and function. Nat Prod Rep
19:312–331
Ramella R, Boero O, Alloatti G, Angelone T, Levi R, Gallo MP (2010) Vasostatin 1 activates eNOS
in endothelial cells through a proteoglycan-dependent mechanism. J Cell Biochem 110:70–79
Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK et al (2007) Catecholamine release-
inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid
variant Gly364Ser causes profound changes in human autonomic activity and alters risk for
hypertension. Circulation 115:2271–2281
Sanchez FA, Rana R, Kim DD, Iwahashi T, Zheng R, Lal BK et al (2009) Internalization of eNOS
and NO delivery to subcellular targets determine agonist-induced hyperpermeability. Proc Natl
Acad Sci U S A 106:6849–6853
Schafer DA (2004) Regulating actin dynamics at membranes: a focus on dynamin. Traffic
5:463–469
Shaul PW (2002) Regulation of endothelial nitric oxide synthase: location, location, location.
Annu Rev Physiol 64:749–774
Signalling Pathways of CgA-Derived Peptides in Cardiac and endothelial cells